Allurion Gastric Balloon System for the Treatment of Adults with Obesity

What is the Purpose of this Study?

The purpose of this study is to evaluate the safety and potential advantages of an investigational device called the Allurion Gastric Balloon System (AGBS), which has been developed for the treatment of adult individuals who are obese. The main component of the AGBS is the Allurion Balloon, which is made up of a thin membrane that takes on an ellipsoid shape in the stomach when it is filled by the filling system. First, the balloon will be empty and rolled up into a small, soft capsule; it is delivered into the stomach by swallowing. The Balloon is designed to reside in the stomach for approximately 16 weeks, after which it breaks down and releases all the fluid. Following emptying, it transits the remainder of the GI tract and is naturally excreted. The Allurion Balloon has been tested in other studies, and the results suggest that it may be useful in reducing weight.

Eligibility

1. Age ≥22 years and ≤ 65 years of age
2. BMI ≥30 kg/m2 and ≤ 40 kg/m2
3. Have signed study-specific Informed Consent Form
4. Willing to comply with study requirements, including follow-up visits

Inclusion Criteria:

1. Age ≥22 years and ≤ 65 years of age
2. BMI ≥30 kg/m2 and ≤ 40 kg/m2
3. Have signed study-specific Informed Consent Form
4. Willing to comply with study requirements, including follow-up visits
5. Documented negative pregnancy test in women of childbearing potential
6. Women of childbearing potential not intending to become pregnant for the duration of study participation. (Note: Women of childbearing potential must not be nursing at the time of treatment).
7. Fully ambulatory without any severe chronic orthopedic disease that requires reliance on crutches, walkers, or a wheelchair that could preclude exercise during the study
8. At least one unsuccessful attempt at weight loss, such as self-administered, commercial, or medically supervised lifestyle therapy program attempted within the 24 months preceding enrollment

Exclusion Criteria:

1. Unable to walk 400 meters (the length of one loop of a track and field race track) without the use of an assistance device (e.g. cane, crutches, walker, wheel chair)
2. Symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery disease
3. Pre-existing significant respiratory disease such as chronic obstructive pulmonary disease (COPD), severe sleep apnea and pneumonia
4. Previous bariatric surgery including adjustable gastric band and endoscopic sleeve gastroplasty, or likely to undergo bariatric surgery during the study period
5. Previous use of an intragastric gastric balloon
6. Current use of an intragastric device, PlenityTM and digital weight loss solutions (e.g. Noom or Calibrate)
7. History of any cancer other than non-melanoma skin cancer or papillary thyroid cancer within the last 5 years
8. Benign or malignant gastrointestinal tumors
9. History of chronic pancreatitis or acute pancreatitis within 12 months of enrollment
10. History of, or current, small bowel obstruction
11. History of severe GI motility disorder, such as severe gastroparesis
12. History of any esophageal, gastric, or small bowel surgery
13. History of, or current inflammatory bowel disease
14. Any history of intraperitoneal adhesions
15. Any history of open abdominal or gynecological surgery and/or radiation therapy to the abdomen, with the exception of cesarean sections performed at least 12 months prior to study enrollment
16. History of/or signs and symptoms of/or radiographic evidence of esophageal, gastric, or duodenal disease including, but not limited to hiatal hernia ≥5cm, inflammatory diseases, varices, severe gastroparesis, recent history of gastric or duodenal ulcers, stricture/stenosis, achalasia, severe GERD requiring maximal medical therapy, or LA Grade B, C, or D esophagitis
17. Diagnosis of autoimmune connective tissue disorder (e.g. lupus, erythematous, scleroderma)
18. Immunocompromised due to medications or medical disease or diagnosed with HIV
19. History of genetic or endocrine causes of obesity not adequately controlled by medication, including hypothyroidism
20. Type 1 diabetes or Type 2 diabetes with HgbA1c ≥ 7%, or treated with any anti-diabetic medications other than metformin
21. Significant acute and/or chronic infections
22. Severe coagulopathy defined as INR 1.5 or higher or platelet count \<150, hepatic insufficiency, or cirrhosis
23. Unable or unwilling to discontinue use of aspirin and/or nonsteroidal anti-inflammatory agents (NSAIDs) at least 7 days prior to Allurion Deployment and continuing for 7 days after the Allurion Balloon is excreted
24. Currently taking the following medications (within 30 days prior to enrollment) and/or there is a need or anticipated need for these medications during the study: Excluded Medications Systemic corticosteroids Anticoagulant therapy (e.g., warfarin, dabigatran) or anti-platelet therapy Immunosuppressive therapy (e.g., azathioprine, cyclosporine) Narcotics, opiates, or benzodiazepines Insulin for treatment of diabetes Anti-seizure therapy (e.g., clonazepam, phenytoin) Anti-arrhythmics (e.g., amiodarone)
25. Inability or unwillingness to take anti-emetics during the device residence
26. Prescription or over-the- counter weight loss medication known to cause significant weight gain or weight loss within 90 days of study enrollment through study participation
27. Uncontrolled or severe psychiatric disease other than mild depression with a patient health questionnaire score of 9 or below
28. History of pulmonary embolism or deep venous thrombosis
29. Has cardiac pacemaker or other electric implantable device
30. Anemia defined as either:
Hgb \<11 g/dL for females, \<12 g/dL for males
31. Cessation of any nicotine product within 3 months of enrollment or plans to quit use during the study
32. Documented total body weight loss of ≥ 5% anytime 6 months preceding enrollment
33. Residing in a location without access to study site medical resources
34. History of or currently active eating disorders including night eating syndrome (NES), bulimia, or binge eating disorder
35. Unwilling to refrain from any reconstructive and/or cosmetic surgery that may affect body weight during the study such as mammoplasty and lipoplasty
36. Current, or history of, illicit drug use (defined per state law) or excessive alcohol use
37. Enrolled in another investigational study that has not completed the required primary endpoint follow-up period (Note: Subjects involved in a long-term surveillance phase of another study are eligible for enrollment in this study).
38. Current Use (within the last month) of any smoked or non-smoked marijuana products that contain THC or unwilling to abstain from THC containing marijuana products during the trial.
39. Any conditions that, in the opinion of each site investigator, may render the subject unable to complete the study with a likely final outcome, or lead to difficulties for subject compliance with study requirements, or could confound study data.
40. Subject is not of sufficient medical health as determined by the Investigator to participate in the study.
41. Employees/family members of Allurion Technologies or any of its affiliates or contractors
42. Immediate employees/family members of the Investigator, sub- Investigators, or their medical office or practice, or surgical, bariatric or hospital organizations at which study procedures may be performed
43. An immediate family member (by marriage or blood relationship) of another subject already enrolled in the study
44. Positive breath or stool test for H. Pylori
45. History of covid-19 with any residual symptoms
46. Known or suspected allergies to polyurethane
47. Uncontrolled high blood pressure defined as ≥160/100 mmHg with or without medications
48. Uncontrolled high cholesterol or triglycerides defined as LDL ≥190 mg/dL or triglycerides ≥500 mg/dL
49. Inability to swallow Allurion Practice Capsule

Show less

Where can I participate?

Beverly

More about this Clinical Trial

What is the full name of this clinical trial?

A Prospective, Open-Label, Multi-Center, Randomized, Pivotal Safety and Efficacy Study of the Allurion Gastric Balloon System + Moderate Intensity Lifestyle Modification Therapy Program vs. Moderate Intensity Lifestyle Modification Therapy Program for the Treatment of Adults with Obesity A Prospective, Open-Lbl, Multi-Ctr, Random, Pivotal Safety & Efficacy Study of Allurion Gastric Balloon Sys + Mod Intensity Lifestyle Modification Therapy vs Mod Intensity Lifestyle Modification Therapy for Treatment of Adults w/Obesity

Study Details

Disease Type/Condition

Obesity, Weight management

Principal Investigator

Watson, Rabindra

Age Group

Adult

Phase

N/A

IRB Number

STUDY00002046

ClinicalTrials.gov ID

NCT05368259

Key Eligibility

ClinicalTrials.gov

How do I learn more about this study?

clinicaltrials@cshs.org